ReviewLeukemia2011
Do we have to kill the last CML cell?
Review in Leukemia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients.NPJ systems biology and applications · 2024Article
- Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.Journal of hematology & oncology · 2023Article
- Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.Annals of hematology · 2022Article
- Treatment-free remission in patients with chronic myeloid leukaemia.Nature reviews. Clinical oncology · 2020Review
- Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.Leukemia · 2020Article
- Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells.Blood and lymphatic cancer : targets and therapy · 2019Review
- Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?HemaSphere · 2018Article
- Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.International journal of hematology · 2018Review
- Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.Blood · 2013Article
- Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy.British journal of haematology · 2012Article
- Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.Haematologica · 2012Article
- The evolving concept of cancer and metastasis stem cells.The Journal of cell biology · 2012Review
- Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2012Article
- Cancer stem cells: an evolving concept.Nature reviews. Cancer · 2012Review
- Antigens in chronic myeloid leukemia: implications for vaccine development.Cancer immunology, immunotherapy : CII · 2011Review
- Article
- Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.Oncotarget · 2011Article
- Article
- In search of CML stem cells' deadly weakness.Current hematologic malignancy reports · 2011Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous experience in the treatment of chronic myeloid leukaemia (CML) has shown that the achievement of clinical, morphological and cytogenetic remission does not indicate eradication of the disease. A complete molecular response (CMR; no detectable BCR-ABL mRNA) represents a deeper level of response, but even CMR is not a guarantee of elimination of the leukaemia, because the significance of CMR is determined by the detection limit of the assay that is used. Two studies of imatinib cessation in CMR are underway, cumulatively involving over 100 patients. The current estimated rate of stable CMR after stopping imatinib is approximately 40%, but the duration of follow-up is relatively short. The factors that determine relapse risk are yet to be identified. The intrinsic capacity of any residual leukaemia [corrected] cells to proliferate following the withdrawal of treatment may be important, but there may also be a role for immunological suppression of the leukaemia [corrected] clone. No currently available test can formally prove that the leukaemic clone is eradicated. Here we discuss the sensitive measurement of minimal residual disease, and speculate on the biology of BCR-ABL-positive cells that may persist after effective therapy of CML.
Indexed as
Identifiers
20844563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.